Page last updated: 2024-12-05

nisone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Nisone: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID91438
CHEMBL ID1507567
CHEBI ID34655
SCHEMBL ID180409
MeSH IDM0174894

Synonyms (64)

Synonym
prednisone, 21-acetate
prednisone acetate
nsc10965
pregna-1,11,20-trione, 17,21-dihydroxy-, 21-acetate
nsc-10965
deltalone
cortancyl
.delta.'-dehydrocortisone acetate
125-10-0
.delta.1-cortisone-21-acetate
prednisone 21-acetate
nisone
pregna-1,11,20-trione, 21-(acetyloxy)-17-hydroxy-
u 6167
delta-corlin
.delta.-corlin
delcortin
delta'-dehydrocortisone acetate
1,4-pregnadien-17-alpha,21-diol-3,11,20-trione-21-acetate
nsc 10965
pregna-1,4-diene-3,11,20-trione, 21-(acetyloxy)-17-hydroxy-
brn 2342061
pregna-1,4-diene-3,11,20-trione, 17,21-dihydroxy-, 21-acetate
delta1-cortisone-21-acetate
einecs 204-726-0
CHEBI:34655 ,
17-hydroxy-3,11,20-trioxopregna-1,4-dien-21-yl acetate
1,4-pregnadien-17alpha,21-diol-3,11,20-trione-21-acetate
21-acetoxy-17alpha-hydroxypregna-1,4-diene-3,11,20-trione
MLS001164126
smr000539571
D08416
[2-[(8s,9s,10r,13s,14s,17r)-17-hydroxy-10,13-dimethyl-3,11-dioxo-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate
NCGC00246186-01
HMS2877O11
unii-ou93qel83u
ou93qel83u ,
4-08-00-03532 (beilstein handbook reference)
AKOS015901581
S5489
CHEMBL1507567
prednisone-21-acetate
prednisone acetate [mart.]
prednisone 21-acetate [mi]
prednisone impurity e [ep impurity]
prednisone acetate [who-dd]
SCHEMBL180409
17-hydroxy-3,11,20-trioxopregna-1,4-dien-21-yl acetate, (17.alpha.)- #
delta-1-dehydrocortison acetate
21-(acetyloxy)-17-hydroxypregna-1,4-diene-3,11,20-trione
.delta.1-dehydrocortisone acetate
1,4-pregnadien-17.alpha.,21-diol-3,11,20-trione-21-acetate
DTXSID20154539
J-005194
DB14646
mfcd00200229
Q27116200
AS-12961
BCP11153
CS-0013902
HY-B1832
EN300-23248413
2-[(1r,3as,3bs,9ar,9bs,11as)-1-hydroxy-9a,11a-dimethyl-7,10-dioxo-1h,2h,3h,3ah,3bh,4h,5h,7h,9ah,9bh,10h,11h,11ah-cyclopenta[a]phenanthren-1-yl]-2-oxoethyl acetate
21-(acetyloxy)-17-hydroxy-pregna-1,4-diene-3,11,20-trione
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (7)

ClassDescription
steroid ester
20-oxo steroidAn oxo steroid carrying an oxo group at position 20.
acetate esterAny carboxylic ester where the carboxylic acid component is acetic acid.
17alpha-hydroxy steroidThe alpha-stereoisomer of 17-hydroxy steroid.
11-oxo steroidAny oxo steroid that has an oxo substituent at position 11.
3-oxo-Delta(1),Delta(4)-steroidA 3-oxo-Delta(1) steroid containing an additional double bond between positions 4 and 5.
tertiary alpha-hydroxy ketoneAn alpha-hydroxy ketone in which the carbonyl group and the hydroxy group are linked by a carbon bearing two organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency3.35870.003245.467312,589.2998AID2517
IDH1Homo sapiens (human)Potency0.01300.005210.865235.4813AID686970
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID540317
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency0.09200.00419.984825.9290AID504444
histone-lysine N-methyltransferase 2A isoform 2 precursorHomo sapiens (human)Potency14.12540.010323.856763.0957AID2662
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID188016Anti-inflammatory effect in rat granuloma assay, activity relative to hydrocortisone and hydrocortisone 21-acetate1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
Structure-activity relationships in the antiinflammatory steroids: a pattern-recognition approach.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (37.50)18.7374
1990's0 (0.00)18.2507
2000's1 (12.50)29.6817
2010's3 (37.50)24.3611
2020's1 (12.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]